Purdue Pharma, LP | Purdue Pharma | Connecticut | state | 2001 | $3,000,000 | | grant/loan hybrid program |
Hospira, Inc. and Subsidiaries | Pfizer | Illinois | state | 2005 | $3,000,000 | | grant |
Centocor, Inc. | Johnson & Johnson | Pennsylvania | state | | $3,000,000 | | tax credit/rebate |
Shire Human Genetic Therapies, Inc | Takeda Pharmaceutical | Massachusetts | state | 2012 | $3,000,000 | | tax credit/rebate |
Exelixis, Inc. | Exelixis | California | state | 2019 | $3,000,000 | | tax credit/rebate |
Bausch & Lomb Incorporated(2) | Bausch Health | New York | state | 2019 | $3,000,000 | | tax credit/rebate |
Bristol Myers Squibb Company | Bristol-Myers Squibb | Arizona | state | 2022 | $3,000,000 | | tax credit/rebate |
SmithKline Beecham Corporation DBA GlaxoSmithKline | GlaxoSmithKline | Pennsylvania | state | 2008 | $2,990,917 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | local | 2017 | $2,960,521 | | tax credit/rebate |
Pfizer, Inc. | Pfizer | New York | state | 2003 | $2,956,000 | | enterprise zone |
Merck & Co., Inc. | Merck | North Carolina | state | 2008 | $2,940,954 | | tax credit/rebate |
Hospira, Inc. and Subsidiaries | Pfizer | Illinois | state | 2008 | $2,872,836 | | tax credit/rebate |
SYNTHES (U.S.A.) | Johnson & Johnson | New York | state | 2007 | $2,870,000 | | enterprise zone |
Wyeth Holdings Corporation | Pfizer | North Carolina | state | 2009 | $2,868,194 | | tax credit/rebate |
OSI Pharmaceuticals/(OSI) Ardsley | Astellas Pharma | New York | local | 2010 | $2,865,573 | | tax credit/rebate; property tax abatement |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2008 | $2,849,428 | | tax credit/rebate; property tax abatement |
Emergent Biosolutions | Emergent BioSolutions | Michigan | state | 2012 | $2,821,980 | | tax increment financing |
Sanofi-Aventis U.S. LLC and Sanofi-Aventis U.S. In | Sanofi | New Jersey | state | 1997 | $2,784,000 | | grant |
Pfizer, Inc. | Pfizer | New York | state | 2002 | $2,783,900 | | enterprise zone |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | Florida | state | 2014 | $2,779,200 | | tax credit/rebate |
Merck & Co., Inc. | Merck | North Carolina | state | 2011 | $2,774,342 | | tax credit/rebate |
PBM Nutritionals, LLC | Perrigo | Vermont | state | 2004 | $2,755,595 | | tax credit/rebate; property tax abatement |
ImClone Systems Corporation | Eli Lilly | New Jersey | state | 2001 | $2,755,200 | | grant |
Pfizer, Inc. | Pfizer | Pennsylvania | state | 2009 | $2,715,300 | | tax credit/rebate |
AstraZeneca Pharmaceuticals LP | AstraZeneca | United States | federal | 2012 | $2,713,491 | | federal grant |
SYNTHES (U.S.A.) | Johnson & Johnson | New York | state | 2006 | $2,697,365 | | enterprise zone |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2022 | $2,645,382 | | tax credit/rebate |
Fort Dodge Laboratories, Inc. | Zoetis | Iowa | state | 2007 | $2,617,500 | | enterprise zone |
SYNTHES U.S.A., LLC | Johnson & Johnson | New York | state | 2009 | $2,600,000 | | enterprise zone |
Pfizer, Inc. | Pfizer | Tennessee | local | 2017 | $2,582,313 | | property tax abatement |
Cody Laboratories | Lannett Co. | Wyoming | state | 2012 | $2,531,424 | | grant |
Abbott Laboratories | Abbott Laboratories | Ohio | local | 2019 | $2,530,230 | | tax credit/rebate |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2017 | $2,525,507 | | tax credit/rebate |
Merck Sharp & Dohme Corp. | Merck | North Carolina | state | 2017 | $2,511,374 | | tax credit/rebate |
Aventis Pharmaceuticals | Sanofi | Missouri | local | 2008 | $2,507,992 | | tax increment financing |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Kentucky | state | 2010 | $2,500,000 | | tax credit/rebate |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Kentucky | state | 2015 | $2,500,000 | | tax credit/rebate |
Par Pharmaceutical Companies, Inc. | Endo International | New York | state | 2015 | $2,500,000 | | tax credit/rebate |
Perrigo Company | Perrigo | Michigan | state | 2013 | $2,500,000 | | tax credit/rebate |
Regeneron Pharmaceuticals, Inc. (MH#3) | Regeneron Pharmaceuticals | New York | state | 2022 | $2,500,000 | | tax credit/rebate |
Novozymes, Inc. | Novo Holdings A/S | United States | federal | 2013 | $2,500,000 | | federal grant |
Zoetis, Inc. and Subsidiaries | Zoetis | Iowa | State | 2017 | $2,499,000 | | Tax credit |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2018 | $2,479,491 | | tax credit/rebate |
Eisai, Inc. | Eisai | North Carolina | state | 2012 | $2,467,398 | | tax credit/rebate |
Sanofi-Aventis | Sanofi | Massachusetts | state | 2011 | $2,450,000 | | tax credit/rebate |
BEN VENUE LABORATORIES | Boehringer Ingelheim | Ohio | state | 2001 | $2,439,160 | | enterprise zone |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2017 | $2,436,956 | | tax credit/rebate |
Aldrich Chemical | Merck KGaA (EMD) | Wisconsin | state | 2003 | $2,426,984 | | tax increment financing |
Mylan Technologies, Inc. | Viatris | Vermont | state | 2003 | $2,426,152 | | tax credit/rebate; property tax abatement |
Genentech USA, Inc. | Roche | Kentucky | state | 2006 | $2,400,000 | | tax credit/rebate |
Sun Pharmaceutical Industries, Inc. | Sun Pharmaceuticals | New Jersey | state | 2008 | $2,382,217 | | grant |
SYNTHES U.S.A., LLC | Johnson & Johnson | New York | state | 2011 | $2,366,358 | | enterprise zone |
GlaxoSmithKline, LLC ( f/k/a SmithKline Beecham Corporation) | GlaxoSmithKline | Pennsylvania | state | 2013 | $2,357,066 | | tax credit/rebate |
Aventis Pharmaceuticals | Sanofi | Missouri | local | 2012 | $2,352,115 | | tax increment financing |
Idexx Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2021 | $2,334,260 | | enterprise zone |
SYNTHES U.S.A., LLC | Johnson & Johnson | New York | state | 2013 | $2,311,702 | | enterprise zone |
Perrigo Company | Perrigo | Michigan | state | 2013 | $2,300,000 | | tax credit/rebate |
Aventis Pharmaceuticals | Sanofi | Missouri | local | 2010 | $2,288,978 | | tax increment financing |
GlaxoSmithKline, LLC (f/k/a SmithKline Beecham Corporation) | GlaxoSmithKline | Pennsylvania | state | 2015 | $2,269,398 | | tax credit/rebate |
Hospira, Inc. | Pfizer | North Carolina | state | 2017 | $2,266,743 | | tax credit/rebate |
Durata Therapeutics, Inc. | AbbVie | Connecticut | state | 2013 | $2,250,000 | | grant/loan hybrid program |
Novartis Vaccines & Diagnostics | Novartis | North Carolina | state | 2010 | $2,250,000 | | grant |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | Massachusetts | state | 2016 | $2,250,000 | | tax credit/rebate |
Johnson & Johnson Health Care Systems Inc. | Johnson & Johnson | Indiana | state | 2020 | $2,250,000 | | tax credit/rebate |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | Massachusetts | state | 2019 | $2,250,000 | | tax credit/rebate |
BEN VENUE LABORATORIES, INC. | Boehringer Ingelheim | Ohio | state | 2005 | $2,246,703 | | enterprise zone |
Aventis Pharmaceuticals | Sanofi | Missouri | local | 2011 | $2,224,018 | | tax increment financing |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | Local | 2018 | $2,211,471 | | tax credit/rebate |
Novartis #2 | Novartis | New Jersey | state | 2005 | $2,208,840 | | Tax credit/rebate |
Janssen Research & Development, LLC (f/k/a J&J Pharmaceutical Research & Development LLC) | Johnson & Johnson | Pennsylvania | state | 2014 | $2,207,905 | | tax credit/rebate |
SYNTHES U.S.A., LLC | Johnson & Johnson | New York | state | 2008 | $2,196,897 | | enterprise zone |
Merck Sharp & Dohme Corp. | Merck | North Carolina | state | 2018 | $2,189,941 | | tax credit/rebate |
NOVO NORDISK RESEARCH CENTER SEATTLE, INC. | Novo Holdings A/S | Washington | state | 2017 | $2,185,140 | | tax credit/rebate |
Regeneron Building D | Regeneron Pharmaceuticals | New York | local | 2022 | $2,171,758 | | tax credit/rebate |
AstraZeneca Pharmaceuticals, LP | AstraZeneca | Maryland | state | 2018 | $2,161,115 | | tax credit/rebate |
OMEROS CORPORATION | Omeros Corp. | Washington | state | 2019 | $2,138,039 | | tax credit/rebate |
Omeros Corporation | Omeros Corp. | Washington | state | 2020 | $2,125,967 | | tax credit/rebate |
Omeros Corporation | Omeros Corp. | Washington | state | 2021 | $2,125,967 | | tax credit/rebate |
Eli Lilly and Company | Eli Lilly | Pennsylvania | state | 2011 | $2,114,575 | | tax credit/rebate |
Ultragenyx Pharmaceutical, Inc. | Ultragenyx Pharmaceutical | California | state | 2014 | $2,100,000 | | tax credit/rebate |
Versum Materials, Inc. | Merck KGaA (EMD) | Arizona | state | 2017 | $2,100,000 | | tax credit/rebate |
Protein Sciences Corporation/MEDCO | Sanofi | Connecticut | state | 1992 | $2,099,074 | | grant/loan hybrid program |
Pharmavite LLC | Otsuka Pharmaceutical | Ohio | state | 2022 | $2,080,000 | | tax credit/rebate |
Takeda Pharmaceuticals North America, Inc. | Takeda Pharmaceutical | Illinois | state | 2008 | $2,034,824 | | tax credit/rebate |
Doral Arrowwood (Pfizer) | Pfizer | New York | local | 2006 | $2,022,893 | | tax credit/rebate; property tax abatement |
PFIZER, INC. | Pfizer | Missouri | state | 2007 | $2,000,000 | | training reimbursement |
Centocor, Inc. | Johnson & Johnson | Pennsylvania | state | | $2,000,000 | | grant |
Shire Pharmaceuticals, Inc. | Takeda Pharmaceutical | Pennsylvania | state | | $2,000,000 | | grant |
Wyeth Pharmaceuticals | Pfizer | Virginia | state | 2004 | $2,000,000 | | grant |
Roche Diagnostics Operations, Inc. | Roche | Indiana | state | 2012 | $2,000,000 | | tax credit/rebate |
Protein Sciences Corp | Sanofi | New York | state | 2015 | $2,000,000 | | tax credit/rebate |
Emergent BioSolutions Inc. | Emergent BioSolutions | Maryland | state | 2015 | $2,000,000 | | grant/loan hybrid program |
Spark Therapeutics, Inc. | Roche | Pennsylvania | state | 2019 | $2,000,000 | | grant |
Elanco Us Inc. | Elanco Animal Health | Indiana | state | 2021 | $2,000,000 | | tax credit/rebate |
Elanco Us Inc. | Elanco Animal Health | Indiana | state | 2021 | $2,000,000 | | tax credit/rebate |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2016 | $1,998,998 | | tax credit/rebate |
SYNTHES (U.S.A.) | Johnson & Johnson | New York | state | 2005 | $1,985,000 | | enterprise zone |
SYNTHES U.S.A., LLC | Johnson & Johnson | New York | state | 2010 | $1,980,000 | | enterprise zone |
Fort Dodge Animal Health | Zoetis | Iowa | state | 2004 | $1,975,500 | | tax credit/rebate |
Barr Laboratories, Inc. and Subsidiaries | Teva Pharmaceutical Industries | New Jersey | state | 2002 | $1,969,200 | | grant |
Idexx Laboratories, Inc. | IDEXX Laboratories | Maine | state | 2019 | $1,954,481 | | enterprise zone |